Sun Pharma declines after US FDA classifies Baska facility inspection as OAI

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

23 December 2025 00:00:00

Adani Ports

1493.75

(-0.97%)

Asian Paints

2808.25

(0.04%)

Axis Bank

1224.70

(-0.68%)

Bajaj Finance

1011.40

(0.39%)

Bajaj Finserv

2047.35

(-0.16%)

Bharat Electro..

399.35

(0.11%)

Bharti Airtel

2122.40

(-1.15%)

Eternal

284.40

(-0.84%)

HCL Technologi..

1678.90

(0.53%)

HDFC Bank

996.40

(0.91%)

Hind. Unilever

2301.40

(0.54%)

ICICI Bank

1363.05

(-0.39%)

Infosys

1668.10

(-1.28%)

Interglobe Avi..

5154.80

(0.22%)

ITC

407.65

(1.27%)

Kotak Mah. Ban..

2161.85

(0.55%)

Larsen & Toubr..

4059.15

(-0.30%)

M & M

3624.80

(0.29%)

Maruti Suzuki

16577.15

(-0.39%)

NTPC

323.20

(0.75%)

Power Grid Cor..

266.95

(0.74%)

Reliance Indus..

1570.90

(-0.29%)

SBI

971.85

(-0.25%)

Sun Pharma.Ind..

1755.20

(-0.91%)

Tata Steel

170.90

(1.03%)

TCS

3310.50

(-0.43%)

Tech Mahindra

1632.10

(-0.88%)

Titan Company

3922.55

(-0.25%)

Trent

4189.95

(-0.39%)

UltraTech Cem.

11675.60

(1.24%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

Sun Pharma declines after US FDA classifies Baska facility inspection as OAI	Share Back
(18 Dec 2025)
The American drug regulator had inspected the company’s facility from 8 September 2025 to 19 September 2025. The US FDA has subsequently determined that the inspection classification status of this facility is Official Action Indicated (OAI). “We continue to manufacture and supply approved products from the facility to the US market. We will work with the regulator to achieve fully compliant status,” the company said in a statement. Sun Pharmaceutical Industries is the world’s leading specialty generics company with a presence in innovative medicines, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as global emerging markets. The company had reported 2.6% rise in consolidated net profit to Rs 3,118 crore on a 8.6% increase in revenue to Rs 14,405.2 crore in Q2 FY26 as compared with Q2 FY25.
Top